{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:45:53Z","timestamp":1787946353403,"version":"build-2784847793"},"reference-count":91,"publisher":"The Royal Society","issue":"1957","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The discovery of the epidermal growth factor receptor (EGFR) represents a landmark achievement in biomedical science, laying the foundation for one of the most transformative success stories in oncology. From the early isolation of epidermal growth factor (EGF) by Stanley Cohen and colleagues to the cloning of EGFR and its identification as a receptor tyrosine kinase, these pioneering studies revealed its central role in cellular growth and proliferation and ultimately linked EGFR signalling to cancer. Early research demonstrated that aberrant EGFR activity could drive tumourigenesis, prompting the development of monoclonal antibodies and small-molecule inhibitors to block receptor activation. Initial clinical experience with first-generation tyrosine kinase inhibitors, gefitinib and erlotinib, revealed dramatic responses in select patients with non-small cell lung cancer (NSCLC), leading to the discovery of sensitizing EGFR mutations as predictive biomarkers of response. These insights ushered in the era of precision medicine in oncology, with molecular testing and targeted therapies becoming the standard of care in the diagnosis and treatment of lung cancer. Subsequent development of second- and third-generation inhibitors, including osimertinib, has further extended survival for patients with EGFR-mutant NSCLC. Despite ongoing challenges owing to drug resistance, novel therapeutic strategies and rational drug combinations continue to redefine the treatment landscape, such that the treatment of EGFR-driven lung cancer remains a paradigm for the application of precision medicine to cancer.<\/jats:p>\n                  <jats:p>This article is part of the discussion meeting issue \u2018Epidermal growth factor receptor after 40 years\u2019.<\/jats:p>","DOI":"10.1098\/rstb.2024.0506","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:09:30Z","timestamp":1787814570000},"source":"Crossref","is-referenced-by-count":1,"title":["Looking back on the history of epidermal growth factor receptor mutations in lung cancer"],"prefix":"10.1098","volume":"381","author":[{"given":"Roy S.","family":"Herbst","sequence":"first","affiliation":[{"name":"Dartmouth Cancer Center One Medical Center Drive Lebanon 1 , NH 03756, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-062X","authenticated-orcid":false,"given":"Meina","family":"Wang","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale University 2 , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Politi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine 3 , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"175","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082703092936500_RSTB20240506C1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"2026082703092936500_RSTB20240506C2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0021-9258(19)83739-0","article-title":"Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal","volume":"237","author":"Cohen","year":"1962","journal-title":"J. Biol. Chem."},{"key":"2026082703092936500_RSTB20240506C3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1073\/pnas.72.4.1317","article-title":"Human epidermal growth factor: isolation and chemical and biological properties","volume":"72","author":"Cohen","year":"1975","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092936500_RSTB20240506C4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/257325a0","article-title":"Isolation and structure of urogastrone and its relationship to epidermal growth factor","volume":"257","author":"Gregory","year":"1975","journal-title":"Nature"},{"key":"2026082703092936500_RSTB20240506C5","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1016\/S0021-9258(19)85573-4","article-title":"Epidermal growth factor-receptor-protein kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity","volume":"255","author":"Cohen","year":"1980","journal-title":"J. Biol. Chem."},{"key":"2026082703092936500_RSTB20240506C6","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1021\/bi00548a040","article-title":"Characterization by electrophoresis of epidermal growth factor stimulated phosphorylation using A-431 membranes","volume":"19","author":"King","year":"1980","journal-title":"Biochemistry"},{"key":"2026082703092936500_RSTB20240506C7","volume-title":"NobelPrize.org","author":"Nobel Prize Outreach","year":"1986"},{"key":"2026082703092936500_RSTB20240506C8","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.78.12.7535","article-title":"Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor","volume":"78","author":"Schreiber","year":"1981","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092936500_RSTB20240506C9","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1016\/S0021-9258(17)42857-2","article-title":"Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity","volume":"259","author":"Gill","year":"1984","journal-title":"J. Biol. Chem."},{"key":"2026082703092936500_RSTB20240506C10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1073\/pnas.80.5.1337","article-title":"Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody","volume":"80","author":"Kawamoto","year":"1983","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092936500_RSTB20240506C11","first-page":"511","article-title":"Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors","volume":"1","author":"Sato","year":"1983","journal-title":"Mol. Biol. Med."},{"key":"2026082703092936500_RSTB20240506C12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/15384047.2020.1712829","article-title":"John Mendelsohn's journey in cancer biology and therapy","volume":"21","author":"Kumar","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"2026082703092936500_RSTB20240506C13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/1078-0432.CCR-14-2491","article-title":"CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth","volume":"21","author":"Mendelsohn","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2026082703092936500_RSTB20240506C14","first-page":"125","article-title":"The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies","volume":"13","author":"Mendelsohn","year":"1992","journal-title":"J. Natl Cancer Inst. Monogr."},{"key":"2026082703092936500_RSTB20240506C15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcb.240200207","article-title":"A monoclonal antibody to the human epidermal growth factor receptor","volume":"20","author":"Waterfield","year":"1982","journal-title":"J. Cell Biochem."},{"key":"2026082703092936500_RSTB20240506C16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/313144a0","article-title":"Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin","volume":"313","author":"Libermann","year":"1985","journal-title":"Nature"},{"key":"2026082703092936500_RSTB20240506C17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C18","first-page":"183","article-title":"Altered expression of epidermal growth factor receptors in human bladder and lung tumours","volume":"17","author":"Berger","year":"1986","journal-title":"Princess Takamatsu Symp."},{"key":"2026082703092936500_RSTB20240506C19","first-page":"400","article-title":"Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients","volume":"51","author":"Sozzi","year":"1991","journal-title":"Cancer Res."},{"key":"2026082703092936500_RSTB20240506C20","first-page":"54","article-title":"Cetuximab in non-small-cell lung cancer","volume":"1","author":"Pirker","year":"2012","journal-title":"Transl. Lung Cancer Res."},{"key":"2026082703092936500_RSTB20240506C21","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S1470-2045(13)70498-4","article-title":"Cetuximab and non-small-cell lung cancer: end of the story?","volume":"14","author":"Rossi","year":"2013","journal-title":"Lancet Oncol."},{"key":"2026082703092936500_RSTB20240506C22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"2026082703092936500_RSTB20240506C23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","article-title":"Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099","volume":"28","author":"Lynch","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C24","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"key":"2026082703092936500_RSTB20240506C27","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"2026082703092936500_RSTB20240506C28","doi-asserted-by":"crossref","first-page":"4233s","DOI":"10.1158\/1078-0432.CCR-040005","article-title":"The role of gefitinib in lung cancer treatment","volume":"10","author":"Giaccone","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2026082703092936500_RSTB20240506C29","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026082703092936500_RSTB20240506C30","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C31","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2002.03.038","article-title":"Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial","volume":"20","author":"Herbst","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0093-7754(01)90283-0","article-title":"Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839","volume":"28","author":"Albanell","year":"2001","journal-title":"Semin. Oncol."},{"key":"2026082703092936500_RSTB20240506C33","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C34","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"J.\u00a0Am.\u00a0Med.\u00a0Assoc."},{"key":"2026082703092936500_RSTB20240506C35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0093-7754(03)70013-X","article-title":"Erlotinib (Tarceva): an update on the clinical trial program","volume":"30","author":"Herbst","year":"2003","journal-title":"Semin. Oncol."},{"key":"2026082703092936500_RSTB20240506C36","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C37","first-page":"1004","article-title":"FDA announces fast track approval of new drug for lung cancer","volume":"326","author":"Dyer","year":"2003","journal-title":"Br.\u00a0Med.\u00a0J."},{"key":"2026082703092936500_RSTB20240506C38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/cancers15030629","article-title":"Treatment strategies for non-small cell lung cancer with common EGFR mutations: a review of the history of EGFR TKIs approval and emerging data","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026082703092936500_RSTB20240506C39","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/jnci\/94.22.1668","article-title":"Demand grows for early access to promising cancer drugs","volume":"94","author":"Baldwin","year":"2002","journal-title":"J. Natl Cancer Inst."},{"key":"2026082703092936500_RSTB20240506C40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2013INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C41","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2013INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C42","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (IRESSA Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"2026082703092936500_RSTB20240506C43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C44","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C45","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C46","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"2026082703092936500_RSTB20240506C47","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1158\/0008-5472.CAN-04-1905","article-title":"Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255","volume":"64","author":"Tracy","year":"2004","journal-title":"Cancer Res."},{"key":"2026082703092936500_RSTB20240506C48","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092936500_RSTB20240506C49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1634\/theoncologist.12-1-90","article-title":"Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing","volume":"12","author":"Sequist","year":"2007","journal-title":"Oncologist"},{"key":"2026082703092936500_RSTB20240506C50","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C51","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C52","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"2026082703092936500_RSTB20240506C54","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C55","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"2026082703092936500_RSTB20240506C56","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/ijms20010146","article-title":"First- and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer?","volume":"20","author":"Takeda","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2026082703092936500_RSTB20240506C57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2213-0802-2-2","article-title":"Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer","volume":"2","author":"Stasi","year":"2014","journal-title":"Transl. Respir. Med."},{"key":"2026082703092936500_RSTB20240506C58","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703092936500_RSTB20240506C59","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"2026082703092936500_RSTB20240506C61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"2026082703092936500_RSTB20240506C62","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol."},{"key":"2026082703092936500_RSTB20240506C63","first-page":"3000","article-title":"Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer","volume":"119","author":"Regales","year":"2009","journal-title":"J. Clin. Invest."},{"key":"2026082703092936500_RSTB20240506C64","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"Janjigian","year":"2014","journal-title":"Cancer Discov."},{"key":"2026082703092936500_RSTB20240506C65","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"2026082703092936500_RSTB20240506C66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C69","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C70","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"2026082703092936500_RSTB20240506C72","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. Reply","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C73","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol."},{"key":"2026082703092936500_RSTB20240506C74","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026082703092936500_RSTB20240506C75","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1556-0864(25)00199-6","article-title":"40: amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study","volume":"20","author":"Yang","year":"2025","journal-title":"J. Thoracic Oncol."},{"key":"2026082703092936500_RSTB20240506C76","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C77","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"2026082703092936500_RSTB20240506C78","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"2026082703092936500_RSTB20240506C79","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jtho.2022.11.022","article-title":"Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers","volume":"18","author":"Choudhury","year":"2023","journal-title":"J. Thoracic Oncol."},{"key":"2026082703092936500_RSTB20240506C80","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026082703092936500_RSTB20240506C81","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026082703092936500_RSTB20240506C82","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2026082703092936500_RSTB20240506C83","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"2026082703092936500_RSTB20240506C84","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"2026082703092936500_RSTB20240506C85","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026082703092936500_RSTB20240506C86","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1158\/1078-0432.CCR-24-0466","article-title":"Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling","volume":"30","author":"El Zarif","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2026082703092936500_RSTB20240506C87","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"key":"2026082703092936500_RSTB20240506C88","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026082703092936500_RSTB20240506C89","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat. Med."},{"key":"2026082703092936500_RSTB20240506C90","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s43018-024-00819-9","article-title":"Targeting therapy-persistent residual disease","volume":"5","author":"Sun","year":"2024","journal-title":"Nat. Cancer"},{"key":"2026082703092936500_RSTB20240506C91","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."}],"container-title":["Philosophical Transactions of the Royal Society B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0506\/6162313\/rstb.2024.0506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0506\/6162313\/rstb.2024.0506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:09:42Z","timestamp":1787814582000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/381\/1957\/20240506\/483099\/Looking-back-on-the-history-of-epidermal-growth"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":91,"journal-issue":{"issue":"1957","published-online":{"date-parts":[[2026,8,27]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2024.0506","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"20240506"}}